Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Still Guilty: Three Former Purdue Execs Lose Fight To Overturn Their Exclusion From Gov't Programs

This article was originally published in The Pink Sheet Daily

Executive Summary

"As with plaintiffs' repeated attempts to characterize themselves as innocent third parties to Purdue's misbranding, the court finds plaintiffs' arguments with respect to financial loss reflective of a fundamental misconception of their own plea agreements," the ruling states.

You may also be interested in...



Prison Terms For Corporate Officers Over Food Violations Worry Pharma

Appeals court affirms sentencing of executives who pled guilty to FDCA misdemeanor violations for distribution of salmonella-contaminated eggs; split ruling finds that officers don't need to know they were violating law to be subject to imprisonment.

Acquittal Of Former Warner Chilcott Exec May Make Future Prosecutions More Difficult

Boston jury clears Carl Reichel of conspiring to pay kickbacks to physicians in case involving dinners and speaker fees.

Purdue Execs’ Exclusion Stands But Court Tells HHS To Justify 12-Year Term

The question now is whether HSS Secretary Sebelius will provide a rationale to continue the 12-year exclusion or reduce the length of the exclusion; appeals court upholds HHS’s authority to exclude three former Purdue Pharma executives from federal health care programs, but notes the length of the sanction departs from similar cases.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS071616

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel